TL;DR
Get self-care and calm essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A September 29 MedPage Today roundup highlighted a court fight over noncompete agreements affecting 27 cardiologists in upstate New York, alongside new cardiovascular research and guidance. Findings included functional decline years before cardiovascular disease and an association between GLP-1 drugs and lower stroke risk in people with type 2 diabetes.
Ellis Medicine and St. Peter’s Health Partners are fighting in court over noncompete agreements covering 27 cardiologists in upstate New York, a dispute that could leave patients at risk of losing access to care, according to CBS6, as summarized by MedPage Today on September 29. The same roundup reported new guidance for managing some medicines before surgery and studies examining early cardiovascular risk and stroke outcomes.
The New York dispute centers on whether the cardiologists’ noncompete agreements can be enforced, according to the roundup. CBS6 reported that patients risk losing care as the health organizations battle in court. The summary did not give the court’s latest ruling, the terms of the agreements, or how many patients could be affected.
Updated American guidance on cardiovascular management around noncardiac surgery carries a strong recommendation to stop SGLT-2 inhibitors three to four days before surgery, according to the report citing Circulation. Separately, a nested case-control study found that functional decline could be apparent as early as a decade before a cardiovascular disease event. The study’s authors said the finding points to a long period when people at higher risk might be identified; the roundup did not provide effect sizes or describe a screening approach.
In a Swedish nationwide study, GLP-1 drugs were associated with a lower stroke risk among people with type 2 diabetes, while SGLT-2 and DPP-4 inhibitors showed neutral effects, according to eClinicalMedicine. A secondary analysis of ANGEL-TNK found that the benefit of intra-arterial tenecteplase after successful endovascular thrombectomy persisted to 12 months. These are study findings, not proof that the drugs or treatment will have the same effects for every patient.
Patient Access and Earlier Risk Signals
The court case has a direct local care dimension: if cardiologists leave or cannot continue treating patients in the region, people may face disruption or have to seek care elsewhere. The available report identifies a risk, but does not establish that patients have already lost access or describe the scale of any disruption.
The research findings address different points in cardiovascular care. A possible decade-long period of functional decline before a CVD event could inform how researchers study earlier identification, while the Swedish drug analysis may help shape questions for further research on stroke prevention. The surgical medication recommendation also has immediate practical relevance for clinicians planning procedures, although individual medication decisions depend on clinical circumstances.
Studies Across Cardiovascular Care
The September 29 item was a short MedPage Today roundup of developments across cardiology, stroke care, surgery, and related fields. Its entries draw on news coverage, updated guidance, clinical trials, observational research, and reports; those source types carry different limits and should not be treated as interchangeable evidence.
Other items included an imaging biomarker associated with the no-reflow phenomenon after stroke thrombectomy despite strong reopening of larger vessels, and a report that transcatheter tricuspid valve interventions were increasingly used in routine practice by the end of 2025, with treated patients broadly resembling pivotal-trial populations and outcomes described as acceptable. The roundup also cited a phase II trial of investigational tipelukast for hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes. MediciNova reported promising safety and efficacy data; the summary did not provide trial numbers or establish the drug’s effectiveness.
Additional findings covered modest associations between microbiome-targeted interventions and improved cardiometabolic markers in children, a randomized trial that found no improved outcomes from a permissive blood-pressure target in critically ill children, and a report calling for more heart failure clinics in the South and Appalachia. The roundup also noted FDA clearance reported by Tempus AI for ECG-MR software intended to identify signs of mitral regurgitation from standard ECGs, and a study validating a transplant rejection biomarker. These items show the breadth of the roundup but do not resolve the New York court dispute.
““A prolonged window for early identification of higher-risk individuals.””
— The nested case-control study authors, as summarized by MedPage Today
Court Outcome and Study Limits
The roundup does not report a decision in the dispute between Ellis Medicine and St. Peter’s Health Partners. It remains unclear whether the agreements will be enforced, whether any cardiologists have left, and how many patients could experience a change in care.
The research summaries also leave key questions open. The Swedish study reports an association between GLP-1 use and stroke risk, but the provided account does not establish cause and effect or give the size of the association. The functional-decline finding does not specify which measures were used or whether acting on them prevents CVD events. The roundup likewise gives no detailed safety or efficacy results for tipelukast.
Court Proceedings and Follow-up Research
The next concrete development in the New York case will be a court ruling or further reporting on the agreements and their effect on local cardiology services. For clinicians, the updated perioperative guidance provides a specific medication timing recommendation, while decisions for individual patients remain a matter for their care teams.
Further publications and follow-up research will be needed to clarify the size and practical meaning of the study findings, including whether the GLP-1 association holds across patient groups and whether earlier detection of functional decline can change outcomes. The roundup does not give publication dates for those next steps.
Key Questions
What is the New York cardiologist dispute about?
Ellis Medicine and St. Peter’s Health Partners are in court over noncompete agreements covering 27 cardiologists, according to the roundup. The available summary does not specify the agreements’ terms or the court’s latest action.
What did the study find about decline before cardiovascular disease?
A nested case-control study reported that functional decline may be apparent as early as a decade before a CVD event. The summary does not say that screening for decline has been shown to prevent those events.
What did the Swedish study report about GLP-1 drugs and stroke?
It found an association between GLP-1 drug use and reduced stroke risk among people with type 2 diabetes. SGLT-2 and DPP-4 inhibitors showed neutral effects in the study; the summary does not establish that GLP-1 drugs caused the lower risk.
Which medicines should be stopped before noncardiac surgery?
The updated American guidance strongly recommends discontinuing SGLT-2 inhibitors three to four days before noncardiac surgery. Patients should discuss medication timing with their clinicians.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
